Theravance Biopharma Inc's Customers Performance

Name: Theravance Biopharma Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

TBPH

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


TBPH's Source of Revenues		During the corresponding time, Theravance Biopharma Inc saw a revenue deteriorated by -20.86 % year on year, sequentially revenue grew by 17.13 %. While revenue at the Theravance Biopharma Inc 's corporate clients • List of TBPH Customers

for the same period Theravance Biopharma Inc revnue deteriorated by -20.86 % year on year, sequentially revenue grew by 17.13 %.

• List of TBPH Customers

Theravance Biopharma Inc's Business Units


Collaborative Arrangement Revenue	185.37 %	of total Revenue
Yupelri Monotherapy	224.71 %	of total Revenue
Single reportable segment	185.37 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Theravance Biopharma Inc's Comment on Sales, Marketing and Customers

The company operates in the US COPD patient market with YUPELRI (revefenacin) inhalation solution, a nebulized long-acting muscarinic antagonist approved for maintenance treatment of COPD. It addresses a segment of COPD patients in the US who require or prefer nebulized delivery for maintenance therapy. YUPELRI was co-developed with Viatris Inc., which leads its commercialization in the US and internationally, excluding China and adjacent territories. The company co-promotes YUPELRI in the US under a profit and loss sharing agreement with Viatris. Additionally, the company sold its remaining royalty interest in global net sales of TRELEGY to GSK plc and receives milestone payments related to TRELEGY sales. Commercial partners include Viatris Inc. and GSK plc.

Theravance Biopharma Inc’s Comment on Sales, Marketing and Customers

TBPH's Stock Performance relative to it's Customers

TBPH's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Theravance Biopharma inc	879.89	104.31	53.81	90
SUBTOTAL	0.00	0.00	0.00	-

Sources: Theravance Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Theravance Biopharma inc’s corporate clients.
For your research, we’ve provided 9 tables on Theravance Biopharma inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.